The stock of Vor Biopharma Inc (VOR) has seen a 12.46% increase in the past week, with a -21.36% drop in the past month, and a -52.55% decrease in the past quarter. The volatility ratio for the week is 10.97%, and the volatility levels for the past 30 days are at 10.20% for VOR. The simple moving average for the past 20 days is -6.79% for VOR’s stock, with a -31.88% simple moving average for the past 200 days.
Is It Worth Investing in Vor Biopharma Inc (NASDAQ: VOR) Right Now?
The 36-month beta value for VOR is at -0.22. Analysts have varying views on the stock, with 5 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for VOR is 76.79M, and currently, shorts hold a 1.74% of that float. The average trading volume for VOR on April 17, 2025 was 355.20K shares.
VOR) stock’s latest price update
Vor Biopharma Inc (NASDAQ: VOR) has experienced a decline in its stock price by -7.14 compared to its previous closing price of 0.70. However, the company has seen a gain of 12.46% in its stock price over the last five trading days. globenewswire.com reported 2025-03-20 that VCAR33 clinical data update planned for first half of 2025 and trem-cel + Mylotarg clinical data update planned for second half of 2025 Anticipate initiation of the first trem-cel+VCAR33 Treatment System clinical trial in second half of 2025 $55.6 million private placement completed in December 2024 CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period and full year ended December 31, 2024, and provided a business update.
Analysts’ Opinion of VOR
Many brokerage firms have already submitted their reports for VOR stocks, with Wedbush repeating the rating for VOR by listing it as a “Outperform.” The predicted price for VOR in the upcoming period, according to Wedbush is $18 based on the research report published on July 26, 2022 of the previous year 2022.
Goldman, on the other hand, stated in their research note that they expect to see VOR reach a price target of $6. The rating they have provided for VOR stocks is “Neutral” according to the report published on April 27th, 2022.
H.C. Wainwright gave a rating of “Buy” to VOR, setting the target price at $26 in the report published on December 17th of the previous year.
VOR Trading at -32.75% from the 50-Day Moving Average
After a stumble in the market that brought VOR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -66.67% of loss for the given period.
Volatility was left at 10.20%, however, over the last 30 days, the volatility rate increased by 10.97%, as shares sank -22.99% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -53.24% lower at present.
During the last 5 trading sessions, VOR rose by +12.46%, which changed the moving average for the period of 200-days by -35.00% in comparison to the 20-day moving average, which settled at $0.6972. In addition, Vor Biopharma Inc saw -41.44% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VOR starting from Attar Eyal C., who sale 2,227 shares at the price of $1.42 back on Feb 13 ’25. After this action, Attar Eyal C. now owns 126,625 shares of Vor Biopharma Inc, valued at $3,162 using the latest closing price.
EYAL ATTAR, the Officer of Vor Biopharma Inc, proposed sale 2,227 shares at $1.38 during a trade that took place back on Feb 13 ’25, which means that EYAL ATTAR is holding shares at $3,073 based on the most recent closing price.
Stock Fundamentals for VOR
The total capital return value is set at -0.98. Equity return is now at value -94.52, with -64.44 for asset returns.
Based on Vor Biopharma Inc (VOR), the company’s capital structure generated 0.25 points at debt to capital in total, while cash flow to debt ratio is standing at -3.13.
Currently, EBITDA for the company is -121.19 million with net debt to EBITDA at 0.42. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.19.
Conclusion
In conclusion, Vor Biopharma Inc (VOR) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
